For decades, batch regimes on industrial-scale stainless steel fermenters and bioreactors have been the backbone of biomanufacturing where biopharmaceuticals and other value-added products are produced on mass scales.

In recent years and especially since the pandemic, biomanufacturing industries have come to the realization that today’s ever-growing demands cannot be met with current strategies.

While more fermenters and bioreactors on the biomanufacturing floor are helping to mitigate the problem, a parallel endeavor is to find new and effective strategies for increasing productivity. One approach is to adapt fed-batch and intensified perfusion regimes for upstream bioprocessing steps to bring down working volumes and simultaneously increase production.